Categories
Change Password!
Reset Password!
A prospective randomized controlled trial was carried to explore the efficacy and safety of the combination of single cross-linked hyaluronan and a platelet-rich plasma compared to a single platelet-rich plasma alone in 85 individuals with knee osteoarthritis.
In patients with knee osteoarthritis, both combined
injections of intraarticular single crosslinked Hyaluronan and platelet-rich
plasma or a single platelet-rich plasma alone is safe and effective for six
months. But the combination achieved better visual analog scale (VAS) pain
reduction compared to a single platelet-rich plasma at six months.
A prospective randomized
controlled trial was carried to explore the efficacy and safety of the
combination of single cross-linked hyaluronan and a platelet-rich plasma
compared to a single platelet-rich plasma alone in 85 individuals with knee
osteoarthritis.
At each follow-up visit, substantial improvements were noted in VAS pain, SLS, WOMAC, and Lequesne index. Subjects treated with a single platelet-rich plasma witnessed higher improvements in VAS pain compared to subjects treated with combined injections at the one-month follow-up (Table.1).
At
each follow-up visit, no vital between-group differences were noted in various
secondary outcomes, except WOMAC-stiffness and WOMAC-pain scores supporting the
one-injection group at one-month. However, the combined-injection cohort
attained considerably better VAS pain decline at six-month follow-up. No severe
adverse effects were observed after treatment in both study groups.
Both combined injections of single cross-linked hyaluronan
plus platelet-rich plasma and single platelet-rich plasma are favored for
treating knee OA.
Scientific Reports
Comparing efficacy of intraarticular single crosslinked Hyaluronan (HYAJOINT Plus) and platelet-rich plasma (PRP) versus PRP alone for treating knee osteoarthritis
Shu-Fen Sun et al.
Comments (0)